Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 34

Results For "Patient"

5068 News Found

WFNS opens doors to industry in landmark Neurosurgery Innovation Pact with Time Med
News | May 16, 2026

WFNS opens doors to industry in landmark Neurosurgery Innovation Pact with Time Med

The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers


Dr. Reddy’s launches generic semaglutide in Canada
News | May 16, 2026

Dr. Reddy’s launches generic semaglutide in Canada

Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada


Lupin receives USFDA nod for Famotidine injection
Drug Approval | May 15, 2026

Lupin receives USFDA nod for Famotidine injection

Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market


Alembic Pharma receives USFDA tentative approval for Darolutamide tablets
Drug Approval | May 15, 2026

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States


Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer
Clinical Trials | May 15, 2026

Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer

The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents


Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation
Clinical Trials | May 14, 2026

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies


Merck to showcase 100+ oncology studies at 2026 ASCO meeting
R&D | May 14, 2026

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline


Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
News | May 14, 2026

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion


Pfizer scores landmark EU approval for  hemophilia drug HYMPAVZI
Drug Approval | May 14, 2026

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy